Gurnet Point Capital Names David Moore Partner

GPC logo

Cambridge, MA, February 24, 2020: Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on health care, announced today that David Moore has been appointed as a Partner of the firm. Mr. Moore, who brings a proven track record of success with both large pharmaceutical and small biotech companies, joins Gurnet Point from Roivant Sciences, a biopharmaceutical drug development company, where he served as Chief Executive Officer of one of its infectious diseases businesses. He also had executive oversight and governance responsibilities for multiple portfolio companies at Roivant, including seeking new investment opportunities.

Prior to his role at Roivant, Mr. Moore was Senior Vice President, Commercial, at Novo Nordisk US, where he led the successful transformation of the company’s commercial operating model into a purely integrated sales and marketing organization. He led the company through multiple new product launches, including one of the most successful launches in Type 2 Diabetes to-date.  He also sat on Novo Nordisk’s Global Management Board, the Portfolio Commercialization Board and the Development Steering Committee.

Commenting on Mr. Moore’s appointment, Gurnet Point Capital’s Managing Partner, Chris Viehbacher, said: “We are delighted to have Dave join our Gurnet Point Capital team. He brings with him a strong record of accomplishment as well as deep
 knowledge of both big pharma and small biotech. Gurnet Point Capital seeks to use the extensive industry experience and network of its team to support the next generation of entrepreneurial leaders as they develop and scale their businesses.  Dave will be not only a great addition to our team but also be an invaluable coach, mentor and investor for our current and future portfolio companies. We are excited to be able to work alongside him.”

Mr. Moore said: “I am eager to get started at Gurnet Point Capital and to join a team that has built a genuinely exciting and innovative portfolio of biotech and healthcare companies. I look forward to contributing towards the firm’s exciting future as it enters the next phase of its growth, both in helping to identify and then develop new opportunities for investment.”   

Mr. Moore began his career at Ortho-McNeil, a Johnson & Johnson Company business, as a sales representative, progressing through key commercial management roles, including market access, sales leadership, marketing and new product development in a wide variety of therapeutic areas.  He later was named Group Marketing Director at Janssen Pharmaceuticals, another Johnson & Johnson business, before making the transition to biotech and taking the position of VP Global Commercial Operations and later Chief Business Officer at Tranzyme Pharma, where, among other responsibilities, he drove the pre-launch of the company’s primary asset. In 2013, Dave was named Chief Commercial Officer (and latterly also President) at biotech company, Cempra Pharmaceuticals, where he transformed the organization from development stage to commercial ready.